...

Conference Report

CCO Independent Conference Coverage of the 2008 American Association for Cancer Research Annual Meeting

Source: CCO Independent Conference Coverage of the 2008 American Association for Cancer Research Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

CCO Independent Conference Coverage of the 2008 American Association for Cancer Research Annual Meeting


Faculty:

Roy S. Herbst, MD, PhDAndrew X. Zhu, MD, PhD, FACP
  • Roy S. Herbst, MD, PhD
  • Andrew X. Zhu, MD, PhD, FACP

CREDIT INFORMATION

Release Date: June 26, 2008

Expiration Date: June 25, 2009


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Begin the Conference Report

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe recent clinical trial results regarding novel agents used to treat hematologic cancers and solid tumors
  • Cite the use of tyrosine kinase inhibitors in the treatment of solid tumors
  • Discuss novel antibody approaches to cancer therapy

Topics covered include:

  • GDC-0449: A Systemic Hedgehog Pathway Antagonist
  • Sunitinib Monotherapy in Patients With Advanced Hepatocellular Carcinoma
  • Difluoromethyl Ornithine and Sulindac to Prevent Colorectal Adenoma Recurrence
  • Antibody-Directed Enzyme Prodrug Therapy in Advanced Carcinoma
  • Phase I Study of AV-951 In Advanced Solid Tumors
  • Dose Escalation Trial of NPI-2358 in Advanced Solid Tumors
  • Phase III Trial of Keyhole Limpet Hemocyanin With Granulocyte-Macrophage Colony-Stimulating Factor in Follicular Non-Hodgkin's Lymphoma
  • Centromere-Associated Protein E Inhibitor GSK923295A in Advanced Solid Tumors
  • Phase II Study of Cediranib in Patients With Recurrent Glioblastoma
  • The Functional Diffusion Map: Early Imaging Biomarker for OS in High-Grade Glioma
  • Novel Monoclonal Antibody Approaches
  • Dasatinib in the Treatment of Solid Tumors
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.